FOXO4-DRI
A designed peptide that cleared aged ("senescent") cells in mice. It has never been tested in people.
- Evidence
- Primarily preclinical research
- Half-life
- Not known
- Sources
- 2 cited
Is FOXO4-DRI FDA-approved?
Not approved by the FDA. Products sold online as "research chemicals" aren't checked for purity, sterility or dose.
Overview
Senescent cells stop dividing but don't die, and they release inflammatory signals linked to aging. In a 2017 study, FOXO4-DRI cleared these cells in fast-aging and naturally old mice. It has never been tested in people, so its safety in humans is unknown.
How it works
In senescent cells, FOXO4 holds p53 in the nucleus, keeping the cell alive. FOXO4-DRI breaks that grip, freeing p53 to trigger the cell's self-destruct program.
How long does FOXO4-DRI stay in the body?
Not established in people.
What it's studied for
- Senescent cell clearance
- Aging (mice)
- Age-related testosterone decline (mice)
Related: Humanin, Thymosin Alpha-1, SS-31 (Elamipretide), KPV.
Sources
The studies and prescribing labels this page is written from.
- Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell, 2017 PubMed
- FOXO4-DRI alleviates age-related testosterone secretion insufficiency in aged mice. Aging, 2020 PubMed
